Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis ChemomAb Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, has published a research article in JCI Insight that highlights the important role of CCL24 in primary sclerosing cholangitis (PSC). The article includes extensive data showing that Chemomab..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing treatments for central nervous system diseases, provided clinical updates for its investigational programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at their recent R&D Day. The company discussed the results of comprehensive data analysis for TSHA-120, addressing feedback from the U.S..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Viracta Therapeutics' NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. (Nasdaq: VIRX) has announced that its pivotal NAVAL-1 clinical trial has achieved the efficacy threshold for expansion in relapsed or refractory EBV-positive peripheral T-cell lymphoma (R/R EBV+ PTCL). This milestone allows the trial to move into Stage 2, indicating a strong signal of efficacy in treating this type of cancer. The NAVAL-1 trial is a global, multicenter ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative have provided an enrollment update for the (Z)-Endoxifen arm of the ongoing I-SPY 2 clinical trial. Six patients have been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive i..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Susan G. Komen® Announces 2023 Grants to Accelerate Research Discoveries and Improve Outcomes for Breast Cancer Patients

Susan G. Komen® Announces 2023 Grants to Accelerate Research Discoveries and Improve Outcomes for Breast Cancer Patients Published: Jun 28, 2023 &nbsp $19.3 Million in Funding to Leading and Emerging Scientists; Grants will Advance Precision Medicine and Eliminate Disparities in Breast Cancer DALLAS, June 28, 2023 /PRNewswire/ -- Susan G. Komen for the Cure®, the world's leading breast cancer or..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Eloxx Pharmaceuticals Highlights Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Positive Phase 2 Results for ELX-02

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, recently held a key opinion leader (KOL) event to discuss the significant unmet medical needs of patients with Alport syndrome. The event featured two renowned experts in Alport syndrome: Professor Detlef Bockenhauer and Professor Rachel Lennon. Alport syndrome is a rare progressive hereditary glomerul..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB

Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB &nbsp Sirona Biochem Corp. is delighted to announce the development of a promising new set of potential antiviral compounds that will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). These compounds, generated by Sirona's subsidiary TFChem, aim t..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Edesa Biotech's Paridiprubart Shows Promise in Inhibiting Inflammation from Influenza and Other Pathogens

Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study demonstrated that inflammation signaling from multiple pathogens, including Influenza A, coronavirus, and a common bacterium (H. influenzae), was inhibited by Edesa's TLR4 antagonist, paridiprubart. These findings support ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity

ZyVersa Therapeutics, a clinical stage specialty biopharmaceutical company, has announced the publication of an article in Clinical Immunology that demonstrates the association between renal NLRP3 inflammasome activation and lupus nephritis disease activity. Lupus nephritis is characterized by inflammation in the kidney, protein leakage into the urine, and progressive kidney damage. The study fo..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Celmatix, Inc., the leading women’s health biotechnology company focused on ovarian biology, has announced a breakthrough in its novel oral fertility drug program. The program aims to eliminate follicle stimulating hormone (FSH) injections from in vitro fertilization (IVF) and egg freezing protocols, as well as reduce the need for IVF by improving outcomes with ovulation induction and treating m..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms